Related references
Note: Only part of the references are listed.End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age
X. Castellsague et al.
BRITISH JOURNAL OF CANCER (2011)
Incremental Impact of Adding Boys to Current Human Papillomavirus Vaccination Programs: Role of Herd Immunity
Marc Brisson et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
HPV Vaccine against Anal HPV Infection and Anal Intraepithelial Neoplasia
Joel M. Palefsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Cervical adenocarcinoma: Moving towards better prevention
Muhieddine Seoud et al.
VACCINE (2011)
The HPV vaccine: Are dosing recommendations being followed?
Weiyi Tan et al.
VACCINE (2011)
Text message reminders to promote human papillomavirus vaccination
Elyse Olshen Kharbanda et al.
VACCINE (2011)
Human papillomavirus (HPV) vaccine uptake and completion at an urban hospital
Nicholas H. Schluterman et al.
VACCINE (2011)
Impact of vaccinating boys and men against HPV in the United States
Elamin H. Elbasha et al.
VACCINE (2010)
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial
Joakim Dillner et al.
BRITISH MEDICAL JOURNAL (2010)
A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions
Susanne K. Kjaer et al.
CANCER PREVENTION RESEARCH (2009)
Factors Associated With Completion of the Human Papillomavirus Vaccine Series
Tara P. L. Neubrand et al.
CLINICAL PEDIATRICS (2009)
Correlates for Completion of 3-Dose Regimen of HPV Vaccine in Female Members of a Managed Care Organization
Chun Chao et al.
MAYO CLINIC PROCEEDINGS (2009)
Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents - A randomized controlled trial
Keith S. Reisinger et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2007)
Prevalence of HPV infection among females in the United States
Eileen F. Dunne et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women
Stan L. Block et al.
PEDIATRICS (2006)
Vaccination coverage and physician distribution in the United States, 1997
CW LeBaron et al.
PEDIATRICS (2001)
Share Paper
